STERIS plc (STE)
Health Care · Health Care Equipment · US stock · S&P 500 component
$222.66
▼ -1.67 (0.74%)
Fair valueFair
$238 +6.9% to fair value
$119fair band $167–$310$357
Day's range
$221.11 – $226.72
52-week range
$193.97 – $267.14
About STERIS plc
STERIS provides products and services that support infection prevention, sterilization and surgical care. It makes sterilizers, surgical tables and lights, and endoscopy accessories, and it offers sterile processing and reprocessing services to hospitals, drug makers and other customers. Revenue comes from equipment sales, consumable supplies such as cleaning and sterilizing agents, and recurring service contracts, which add a measure of steadiness to results.
Revenue has grown 9.4% a year over three years, leaving the last twelve months at $6.0 billion. Operating margin is 18.9%. Return on invested capital comes to 10%. On leverage, net debt to EBITDA is 0.9 times. A dividend is paid, with a yield of 1.2%. This gives an X-Ray Score of 64 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $193.97 – $267.14Volume 601,400Daily, split-adjusted
Vitals
Market cap$21.8B
52-week range$193.97 – $267.14
Volume (last day)601,400
P/E (TTM)27.2
EBIT / EV yield4.9%
Free-cash-flow yield4.2%
Dividend yield1.2%
Revenue (TTM)$6.0B
Net income (TTM)$805M
Operating margin18.9%
Return on capital9.8%
Debt incl. leases$1.9B
Cash & securities$482M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$238model spread $227 – $251
Fair
+6.9% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $223
Undervalued < $167Fair $167 – $310Overvalued > $310
10-year DCF (market-scaled)
$241
Peer multiples
$223
Earnings power floor (not blended)
$70
Fundamentals-adjusted multiple
$251
Growth the price implies
15.4%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
57/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield4.9%
Free-cash-flow yield4.2%
Fair value vs price1.1×
Growth
Strong
77/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)9.4%
EPS growth (3y)95.0%
Growth consistency100%
Profitability
Weak
49/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital9.8%
Operating margin18.9%
Gross profitability25.0%
Financial health
Strong
78/100
Balance sheet looks strong: debt is well covered.
See the numbers →
Piotroski F-Score9 / 9
Net debt / EBITDA0.9×
Interest cover18.8×
Dividends
Fair
62/100
Dividend is typical for its sector.
See the numbers →
Dividend yield1.2%
Dividends vs free cash flow27%
Dividend growth9.6%
Quarterly results: last 6 quarters
+4.3%
Mar '25
+8.7%
Jun '25
+9.9%
Sep '25
+9.2%
Dec '25
+7.3%
Mar '26
+7.3%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.5B.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 7 Good · ● 8 Average · ● 1 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldAverage
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalAverage
Operating marginAverage
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 63/100.
Financials
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Revenue | $4.2B | $4.5B | $5.1B | $5.5B | $5.9B |
| Operating income | $478M | $791M | $836M | $867M | $1.1B |
| Net income | $244M | $107M | $378M | $615M | $782M |
| Operating cash flow | $685M | $757M | $973M | $1.1B | $1.3B |
| Operating margin | 11.3% | 17.4% | 16.3% | 15.9% | 18.6% |
| Free cash flow | $397M | $395M | $613M | $778M | $972M |
| Diluted EPS | $2.48 | $1.07 | $3.81 | $6.20 | $7.93 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
10 bullish · 3 neutral · 3 bearish
Weekly
Neutral
6 bullish · 1 neutral · 5 bearish
Monthly
Strongly bearish
1 bullish · 1 neutral · 6 bearish
Moving averages (daily)
| SMA 10 | 215.6 | Bullish |
| EMA 10 | 217.1 | Bullish |
| SMA 20 | 212.4 | Bullish |
| EMA 20 | 215.4 | Bullish |
| SMA 50 | 221.1 | Bullish |
| EMA 50 | 217.2 | Bullish |
| SMA 100 | 217.4 | Bullish |
| EMA 100 | 219.2 | Bullish |
| SMA 200 | 225.2 | Bearish |
| EMA 200 | 223.2 | Bearish |
Oscillators (daily)
| RSI (14) | 62.20 | Neutral |
| MACD (12, 26) | 0.80 | Bullish |
| Momentum (12) | 6.02 | Bullish |
| Stochastic %K (14) | 79.89 | Neutral |
| Williams %R (14) | -20.11 | Neutral |
| CCI (20) | 188.8 | Bearish |
Pivot points (classic, last session)
S3 214.7 | S2 217.9 | S1 220.3 | Pivot 223.5 | R1 225.9 | R2 229.1 | R3 231.5 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.58 USD
Yield on today's price
1.16%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 4 Sep 2026 | 0.6900 |
| 8 Jun 2026 | 0.6300 |
| 17 Feb 2026 | 0.6300 |
| 18 Nov 2025 | 0.6300 |
| 4 Sep 2025 | 0.6300 |
| 10 Jun 2025 | 0.5700 |
| 20 Feb 2025 | 0.5700 |
| 19 Nov 2024 | 0.5700 |
| 5 Sep 2024 | 0.5700 |
| 12 Jun 2024 | 0.5200 |
| 22 Feb 2024 | 0.5200 |
| 20 Nov 2023 | 0.5200 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
STE SEC filings
13 Oct 2026
8-KSEC EDGAR
Entered a material agreement
7 Aug 2026
10-QSEC EDGAR
Quarterly report
6 Aug 2026
8-KSEC EDGAR
Shareholder vote results
5 Aug 2026
8-KSEC EDGAR
Results of operations; Exit or restructuring costs
11 Jun 2026
DEF 14ASEC EDGAR
Proxy statement
29 May 2026
10-KSEC EDGAR
Annual report
11 May 2026
8-KSEC EDGAR
Results of operations
7 May 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.